menu
    • menu
    [{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Wize Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bonus BioGroup","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Bonus BioGroup \/ Bonus BioGroup","highestDevelopmentStatusID":"15","companyTruncated":"Bonus BioGroup \/ Bonus BioGroup"},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Activated Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bonus BioGroup \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioGroup \/ Undisclosed"},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Activated Mesenchymal Stromal Cell","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bonus BioGroup \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioGroup \/ Undisclosed"},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Allogeneic Cell Therapy","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Bonus BioGroup","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bonus BioGroup \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bonus BioGroup \/ Undisclosed"},{"orgOrder":0,"company":"Bonus BioGroup","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MesenCure","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Bonus BioGroup","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bonus BioGroup \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bonus BioGroup \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Bonus BioGroup

    Menu

    Bonus BioGroup

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bonus BioGroup

                            Israel arrow
                            Global ChemShow
                            Not Confirmed

                            Bonus BioGroup

                            Israel arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Cell Therapy

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bonus Biogroup Gets FDA Clearance for MesenCure™ Phase III Study

                            Details : MesenCure is an allogeneic cell therapy investigational drug comprising enhanced adipose tissue-derived MSC designed to treat inflammation and tissue damage in ARDS patients.

                            Product Name : MesenCure

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 20, 2025

                            Lead Product(s) : Allogeneic Cell Therapy

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bonus BioGroup

                            Israel arrow
                            Global ChemShow
                            Not Confirmed

                            Bonus BioGroup

                            Israel arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MesenCure

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Wize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data

                            Details : Treatment with MesenCure reduced fluid in the lungs by 47% compared to untreated subjects, and significantly increased blood lymphocyte counts, which play a key role in fighting viruses.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 27, 2020

                            Lead Product(s) : MesenCure

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bonus BioGroup

                            Israel arrow
                            Global ChemShow
                            Not Confirmed

                            Bonus BioGroup

                            Israel arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Activated Mesenchymal Stromal Cell

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Wize Pharma's Strategic Transaction Partner Bonus BioGroup Reports Successful Treatment of Acute Pneumonia in ...

                            Details : Bonus reported that following treatment with MesenCure, the microscopic appearance of treated lungs was similar to healthy lungs, and a significant improvement in additional parameters was achieved.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 18, 2020

                            Lead Product(s) : Activated Mesenchymal Stromal Cell

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bonus BioGroup

                            Israel arrow
                            Global ChemShow
                            Not Confirmed

                            Bonus BioGroup

                            Israel arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Activated Mesenchymal Stromal Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bonus Biogroup Initiates Preclinical Study for Treatment of Respiratory Distress in COVID-19 Patients

                            Details : Bonus BioGroup's mesenchymal stromal cell (MSC)-based drug MesenCure intended to treat acute respiratory distress resulting from COVID-19 and other causes.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 21, 2020

                            Lead Product(s) : Activated Mesenchymal Stromal Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bonus BioGroup

                            Israel arrow
                            Global ChemShow
                            Not Confirmed

                            Bonus BioGroup

                            Israel arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Recipient : Wize Pharma

                            Deal Size : $7.4 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Wize Pharma Executes Agreements for Strategic Transaction with Bonus BioGroup

                            Details : This agreement will advance Wize Pharma's ongoing clinical program for LO2A, currently in a Phase IV study for the treatment of dry eye syndrome in patients with Sjogren's.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 16, 2020

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Recipient : Wize Pharma

                            Deal Size : $7.4 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth